简介

裴正康(Ching-Hon,Pui)院士是儿童急性淋巴细胞白血病领域最顶尖专家之一。1951年出生于台湾,目前是台湾中央研究院院士、中国工程院外籍院士,美国圣述德儿童研究医院肿瘤系主任。

Oncology MS 260, Room C6056 St. Jude Children’s Research Hospital 262 Danny Thomas Place Memphis, TN 38105-3678, USA

他在儿童白血病生物学和治疗学领域是全球的领军人物,其贡献全球公认,研究和论证的临床研究成果使儿童急性淋巴细胞白血病(ALL)的治愈率超过90%,受益群体由儿童扩展至青少年。率先提出并论证儿童ALL可以通过鞘内化疗和大剂量甲氨蝶呤化疗替代头颅放疗,使全球无数的ALL患儿免受头颅放疗和由此带来的相关近、远期合并症,并因此而使患儿终身受益。创新性地识别白血病相关的特异靶基因并作为治疗靶标使部分难治性ALL得到有效的治疗。证明白血病微量残留病水平监测可指导临床治疗强度的调整,该治疗策略得到全球性认可并广泛应用。2004年至今,在Thomson ISI Essential Science Indicators临床医学排名列Top100,被公认为在儿童急性淋巴细胞性白血病临床诊治与转化研究领域的国际权威。

荣誉

  • 2015 Foreign Member, Chinese Academy of Engineering (中国工程院外籍院士)
  • 2014 Academician, Academia Sinica
  • 2012 Pediatric Oncology Award and Lecture, American Society of Clinical Oncology
  • 2011 ASH Henry M. Stratton Medal Award
  • 2011 Robert A. Phillips Public Lecture and Award, Ontario Institute for Cancer Research
  • 2011 Joseph H. Burchenal Clinical Research Award, AACR
  • 2010 Castle Connolly National Physician of the Year Award for Clinical Excellence
  • 2009 AACR Team Science Award (team leader)
  • 2002 American Cancer Society FM Kirby Clinical Research Professor
  • 1999 Member, Association of American Physicians
  • 1998 Fellow, American Association for the Advancement of Science
  • 1996 Member, American Society for Clinical Investigation

主要研究领域

  • Development of “Total Therapies” for children with leukemia
  • Evaluating the efficacy of novel antileukemic drugs or new therapeutic strategies
  • Applying molecular genetic, pharmacologic and immunologic discoveries to clinical problems

花絮

2016年我们课题组发表了一篇关于急性B淋巴细胞白血病(acute lymphoblastic leukemia,B-ALL)分子分型研究(也是我参与的第一个课题),对近200例儿童和成人B-ALL进行了全景式的基因组和转录组研究 (Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia,两年被引用40+),发现了三种新的由融合基因驱动B-ALL分子亚型(MEF2D. ZNF384,DUX4融合基因受累并与ERG基因缺失共存)。裴院士也是这篇文章的共同作者之一。

2018年4月在上海举行的白血病精准医学国际工作会议,我们课题组作为东道主,请到了裴院士和多位领域内的顶级专家来上海进行交流。除了了解到了许多最新的科学前沿之外,期间我们还有幸可以和裴院士以及多位急性淋巴白血病研究领域的专家夜游黄浦江,确实是非常难忘的一段经历。我们这些晚辈可能真的是需要多和一些这样的”偶像”接触,无论是在品行、学术亦或是对于人生的追求,他们都是我们值得学习的榜样,为了一个坚定的信念为之奋斗一辈子。

最新论文

  • Liu YF, Wang BY, Zhang WN, Huang JY, Li BS, Zhang M, Jiang L, Li JF, Wang MJ, Dai YJ, Zhang ZG, Wang Q, Kong J, Chen B, Zhu YM, Weng XQ, Shen ZX, Li JM, Wang J, Yan XJ, Li Y, Liang YM, Liu L, Chen XQ, Zhang WG, Yan JS, Hu JD, Shen SH, Chen J, Gu LJ, Pei D, Li Y, Wu G, Zhou X, Ren RB, Cheng C, Yang JJ, Wang KK, Wang SY, Zhang J, Mi JQ, Pui CH, Tang JY, Chen Z, and Chen SJ. 2016. Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia. EBioMedicine 8:173-183. 10.1016/j.ebiom.2016.04.038
  • Zhang J, McCastlain K, Yoshihara H, Xu B, Chang Y, Churchman ML, Wu G, Li Y, Wei L, Iacobucci I, Liu Y, Qu C, Wen J, Edmonson M, Payne-Turner D, Kaufmann KB, Takayanagi SI, Wienholds E, Waanders E, Ntziachristos P, Bakogianni S, Wang J, Aifantis I, Roberts KG, Ma J, Song G, Easton J, Mulder HL, Chen X, Newman S, Ma X, Rusch M, Gupta P, Boggs K, Vadodaria B, Dalton J, Liu Y, Valentine ML, Ding L, Lu C, Fulton RS, Fulton L, Tabib Y, Ochoa K, Devidas M, Pei D, Cheng C, Yang J, Evans WE, Relling MV, Pui CH, Jeha S, Harvey RC, Chen IL, Willman CL, Marcucci G, Bloomfield CD, Kohlschmidt J, Mrozek K, Paietta E, Tallman MS, Stock W, Foster MC, Racevskis J, Rowe JM, Luger S, Kornblau SM, Shurtleff SA, Raimondi SC, Mardis ER, Wilson RK, Dick JE, Hunger SP, Loh ML, Downing JR, Mullighan CG, and St. Jude Children’s Research Hospital-Washington University Pediatric Cancer Genome P. 2016. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet. 10.1038/ng.3691
  • Qian M, Zhang H, Kham SK, Liu S, Jiang C, Zhao X, Lu Y, Goodings C, Lin TN, Zhang R, Moriyama T, Yin Z, Li Z, Quah TC, Ariffin H, Tan AM, Shen S, Bhojwani D, Hu S, Chen S, Zheng H, Pui CH, Yeoh AE, and Yang JJ. 2017. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP. Genome Res 27:185-195. 10.1101/gr.209163.116
  • Churchman ML, Qian M, Te Kronnie G, Zhang R, Yang W, Zhang H, Lana T, Tedrick P, Baskin R, Verbist K, Peters JL, Devidas M, Larsen E, Moore IM, Gu Z, Qu C, Yoshihara H, Porter SN, Pruett-Miller SM, Wu G, Raetz E, Martin PL, Bowman WP, Winick N, Mardis E, Fulton R, Stanulla M, Evans WE, Relling MV, Pui CH, Hunger SP, Loh ML, Handgretinger R, Nichols KE, Yang JJ, and Mullighan CG. 2018. Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. Cancer Cell. 10.1016/j.ccell.2018.03.021
  • Pui C-H, Yang JJ, Bhakta N, and Rodriguez-Galindo C. 2018. Global efforts toward the cure of childhood acute lymphoblastic leukaemia. The Lancet Child & Adolescent Health 2:440-454. 10.1016/s2352-4642(18)30066-x
  • Zhang Y, Gao Y, Zhang H, Zhang J, He F, Hnizda A, Qian M, Liu X, Gocho Y, Pui CH, Cheng T, Wang Q, Yang JJ, Zhu X, and Liu X. 2018. PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. Blood. 10.1182/blood-2017-11-817510

代表论著 (来源:2015年主页更新)

  • Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, Vora A, Baruchel A, Silverman LB, Schmiegelow K, Escherich G, Horibe K, Benoit YC, Izraeli S, Yeoh AE, Liang DC, Downing JR, Evans WE, Relling MV, Mullighan CG. Childhood Acute Lymphoblastic Leukemia: progress through collaboration. J Clin Oncol 33(27):2938-48, 2015.
  • Pui CH, Pei D, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, Sandlund JT, Ribeiro RC, Rubnitz JE, Inaba H, Bhojwani D, Gruber TA, Leung WH, Downing JR, Evans WE, Relling MV, Campana D. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol 16(4):465-474, 2015.
  • Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, Hedges D, Ma X, Zhou X, Yergeau DA, Wilkinson MR, Vadodaria B, Chen X, McGee RB, Hines-Dowell S, Nuccio R, Quinn E, Shurtleff SA, Rusch M, Patel A, Becksfort JB, Wang S, Weaver MS, Ding L, Mardis ER, Wilson RK, Gajjar A, Ellison DW, Pappo AS, Pui CH, Nichols KE, Downing JR. Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med 373(24):2336-46, 2015.
  • Mullighan CG, Jeha S, Pei D, Payne-Turner D, Coustan-Smith E, Roberts KG, Waanders E, Choi JK, Ma X, Raimondi SC, Fan Y, Yang W, Song G, Yang JJ, Inaba H, Downing JR, Leung WH, Bowman WP, Relling MV, Evans WE, Zhang J, Campana D, Pui CH. Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. Blood 2015 Nov 2. pii: blood-2015-09-671131.
  • Pui CH, Pei D, Campana D, Cheng C, Sandlund JT, Bowman WP, Hudson MM, Ribeiro RC, Raimondi SC, Jeha S, Howard SC, Bhojwani D, Inaba H, Rubnitz JE, Metzger ML, Gruber TA, Coustan-Smith E, Downing JR, Leung WH, Relling MV, Evans WE. A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia 28(12):2336-43, 2014.
  • Roberts KG, Pei D, Campana D, Payne-Turner D, Li Y, Cheng C, Sandlund JT, Jeha S, Easton J, Becksfort J, Zhang J, Coustan-Smith E, Raimondi SC, Leung WH, Relling MV, Evans WE, Downing JR, Mullighan CG, Pui CH. Outcome of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol 32(27):3012-20, 2014.
  • Yeoh AE, Tan D, Li CK, Hori H, Tse E, Pui CH. Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asia Oncology Summit 2013. Lancet Oncol 14:e508-523, 2013.
  • Pui CH, Evans WE. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol 50(3):185-96, 2013.
  • Krull KR, Bhojwani D, Conklin HM, Pei D, Cheng C, Reddick WE, Sandlund JT, Pui CH. Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 31(17):2182-2188, 2013.
  • Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol 14(6):e205-17, 2013.
  • Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood June 22, 2012.
  • Downing JR, Wilson RK, Zhang J, Mardis ER, Pui CH, Ding L, Ley TJ, Evans WE. The pediatric cancer genome project. Nat Genet 44(6):619-22, 2012.
  • Pui CH, Pei D, Pappo AS, Howard SC, Cheng C, Sandlund JT, Furman WL, Ribeiro RC, Spunt SL, Rubnitz JE, Jeha S, Hudson MM, Kun LE, Merchant TE, Kocak M, Broniscer A, Metzger ML, Downing JR, Leung W, Evans WE, Gajjar A. Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children’s Research Hospital, 1992 through 2007. J Clin Oncol April 30, 2012.
  • Leung W, Pui CH, Coustan-Smith E, Yang J, Pei D, Gan K, Srinivasan A, Hartford C, Triplett BM, Dallas M, Pillai A, Shook D, Rubnitz JE, Sandlund JT, Jeha S, Inaba H, Ribeiro RC, Handgretinger R, Laver JH, Campana D. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood April 19, 2012.
  • Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A, Conter V, Otten J, Ohara A, Versluys AB, Escherich G, Heyman M, Silverman LB, Horibe K, Mann G, Camitta BM, Harbott J, Riehm H, Richards S, Devidas M, Zimmermann M. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 366(15):1371-81, 2012.
  • Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, Lu C, Chen SC, Wei L, Collins-Underwood JR, Ma J, Roberts KG, Pounds SB, Ulyanov A, Becksfort J, Gupta P, Huether R, Kriwacki RW, Parker M, McGoldrick DJ, Zhao D, Alford D, Espy S, Bobba KC, Song G, Pei D, Cheng C, Roberts S, Barbato MI, Campana D, Coustan-Smith E, Shurtleff SA, Raimondi SC, Kleppe M, Cools J, Shimano KA, Hermiston ML, Doulatov S, Eppert K, Laurenti E, Notta F, Dick JE, Basso G, Hunger SP, Loh ML, Devidas M, Wood B, Winter S, Dunsmore KP, Fulton RS, Fulton LL, Hong X, Harris CC, Dooling DJ, Ochoa K, Johnson KJ, Obenauer JC, Evans WE, Pui CH, Naeve CW, Ley TJ, Mardis ER, Wilson RK, Downing JR, Mullighan CG. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481(7380):157-63, 2012.
  • Diouf B, Cheng Q, Krynetskaia NF, Yang W, Cheok M, Pei D, Fan Y, Cheng C, Krynetskiy EY, Geng H, Chen S, Thierfelder WE, Mullighan CG, Downing JR, Hsieh P, Pui CH, Relling MV, Evans WE. Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat Med 17(10):1298-1303, 2011.
  • Leung W, Campana D, Yang J, Pei D, Coustan-Smith E, Gan K, Rubnitz JE, Sandlund JT, Ribeiro RC, Srinivasan A, Hartford C, Triplett BM, Dallas M, Pillai A, Handgretinger R, Laver JH, Pui CH. High success of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood May 25, 2011.
  • Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med 364(19):1844-54, 2011.
  • Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA, Heatley SL, Holmfeldt L, Collins-Underwood JR, Ma J, Buetow KH, Pui CH, Baker SD, Brindle PK, Downing JR. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471(7337):235-9, 2011.
  • Yang JJ, Cheng C, Devidas M, Cao X, Fan Y, Campana D, Yang W, Neale G, Cox NJ, Scheet P, Borowitz MJ, Winick NJ, Martin PL, Willman CL, Bowman WP, Camitta BM, Carroll A, Reaman GH, Carroll WL, Loh M, Hunger SP, Pui CH, Evans WE, Relling MV. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet February 6, 2011.
  • Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol January 1, 2011.
  • Pui CH, Pei D, Campana D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Coustan-Smith E, Jeha S, Cheng C, Metzger ML, Bhojwani D, Inaba H, Raimondi SC, Onciu M, Howard SC, Leung W, Downing JR, Evans WE, Relling MV. Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol December 20, 2010.
  • Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X, Meshinchi S, Degar B, Airewele G, Raimondi SC, Onciu M, Coustan-Smith E, Downing JR, Leung W, Pui CH, Campana D. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol May 5, 2010.
  • Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA, Harvey RC, Chen IM, Clifford RJ, Carroll WL, Reaman G, Bowman WP, Devidas M, Gerhard DS, Yang W, Relling MV, Shurtleff SA, Campana D, Borowitz MJ, Pui CH, Smith M, Hunger SP, Willman CL, Downing JR, Children’s Oncology Group. Deletion of IKZF1 and prognosis in acute lymphoblasic leukemia. N Engl J Med 360:470-480, 2009.
  • Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Coustan-Smith E, Kun LE, Jeha S, Cheng C, Howard SC, Simmons V, Bayles A, Metzger ML, Boyett JM, Leung W, Handgretinger R, Downing JR, Evans WE, Relling MV. Treating childhood acute lymphoblastic leukemia without prophylactic cranial irradiation. N Engl J Med 360:2730-2741, 2009.
  • Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D, Hughes TP, Le Beau MM, Pui C-H, Relling MV, Shurtleff SA, Downing JR. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of lkaros. Nature 453:110-114, 2008.
  • Pui C-H, Howard SC. Current management and challenges in the CNS in paediatric leukaemia. Lancet Oncol 9:257-268, 2008.
  • Pui C-H, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 371:1030-1043, 2008.
  • Pui C-H, Evans WE, Relling MV. Are children with lesser-risk B-lineage acute lymphoblastic leukemia curable with antimetabolite therapy? Nat Clin Pract Oncol 5:130-131, 2008.
  • Mullighan GC, Goorha S, Radtke I, Miller C, Coustan-Smith E, Dalton J, Girtman K, Mathew S, Ma J, Pounds S, Su X, Pui C-H, Relling MV, Evans WE, Shurtleff SA, Downing JR. Genome-wide analysis of genetic alterations in acute lymphoblastic leukemia. Nature 446:758-764, 2007.
  • Iwamoto S, Mihara K, Downing JR, Pui C-H, Campana D. Mesenchymal cells determine the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 117:1049-1057, 2007.
  • Hijiya N, Hudson M, Lensing S, Zacher M, Onciu M, Behm FG, Razzouk BI, Ribeiro RC, Rubnitz JE, Sandlund JT, Rivera GK, Evans WE, Relling MV, Pui C-H. Cumulative incidence of secondary neoplasms as the first event after treatment of childhood acute lymphoblastic leukemia increases over 30 years. JAMA 297:1207-1215, 2007.
  • Pui C-H, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukemia. Nat Rev Drug Discov 6:149-165, 2007.
  • Pui C-H, Evans WE. Treatment for acute lymphoblastic leukemia. N Engl J Med 354:166-178, 2006.
  • Cheng Q, Yang WJ, Raimondi SC, Pui C-H, Relling MV, Evans WE. Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet 37:878-882, 2005.
  • Ribeiro RC, Pui CH. Saving the children-improving childhood cancer treatment in developing countries. N Engl J Med 352:2158-2160, 2005.
  • Holleman A, Cheok MH, den Boer ML, Yang W, Veerman AJP, Kazemier KM, Pei D, Cheng C, Pui C-H, Relling MV, Janka-Schaub GE, Pieters R, Evans WE. Gene expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 351:533-542, 2004.
  • Pui C-H, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 350:1535-1548, 2004.
  • Pui C-H, Sandlund JT, Pei D, Rivera GK, Howard SC, Ribeiro RC, Rubnitz JE, Razzouk BI, Hudson M, Cheng C, Raimondi SC, Behm FG, Downing J, Relling MV, Evans WE. Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA 290:2001-2007, 2003.
  • Pui C-H, Cheng C, Leung W, Rai SN, Rivera GK, Sandlund JT, Ribeirio RC, Relling MV, Kun LE, Evans WE, Hudson MM. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Eng J Med 349:640-649, 2003.
  • Cheok MH, Yang W, Pui C-H, Downing JR, Cheng C, Naeve CW, Relling MV, Evans WE. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 34:85-90, 2003.
  • Pui C-H, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W, Silverman LB, Biondi A, Harms D, Vilmer E, Schrappe M, Camitta B. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 359:1909-1915, 2002.
  • Yeoh E-J, Ross MB, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, Relling MV, Patel A, Cheng C, Campana D, Wilkins D, Zhou X, Li J, Liu H, Pui C-H, Evans WE, Naeve C, Wong L, Downing JR. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1:133-143, 2002.
  • Pui C-H, Campana D, Evans WE. Acute lymphoblastic leukemia – current status and future perspective. Lancet Oncol 2:597-607, 2001.
  • Howard SC, Gajjar A, Ribeirio RC, Rivera GK, Rubnitz JE, Sandlund JT, Harrison PL, deArmendi A, Dahl GV, Pui C-H. Safety of lumbar puncture in children with acute lymphoblastic leukemia and thrombocytopenia. JAMA 284:2222-2224, 2000.
  • Relling MV, Pui C-H, Sandlund JT, Rivera GK, Hancock ML, Boyett JB, Schuetz EG, Evans WE. Adverse effect of anticonvulsants on the efficacy of chemotherapy for acute lymphoblastic leukemia. Lancet 356:285-290, 2000.
  • Aricò M, Valsecchi MG, Camitta B, Schrappe M, Chessels J, Baruchel A, Gaynon P, Sallan S, Janka G, Kamps W, Pui C-H, Masera G. Outcome of treatment of Philadelphia-chromosome positive acute lymphoblastic leukemia. N Engl J Med 342:998-1006, 2000.
  • Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock M, Felix CA, Kun LE, Walter AW, Evans WE,Pui C-H. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 354:34-39, 1999.
  • Pui C-H, Evans WE. Drug Therapy: Acute lymphoblastic leukemia. N Engl J Med 339:605-615, 1998.
  • Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui C-H. Conventional versus individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499-505, 1998.
  • Pui C-H, Boyett JM, Hughes W, Rivera GK, Hancock M, Sandlund JT, Synold T, Relling MV, Ribeirio RC, Crist WM, Evans WE. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. New Engl J Med 336:1781-1787, 1997.
  • Pui C-H. Medical Progress: Childhood leukemias. N Engl J Med 332:1618-1630, 1995.
  • Pui C-H, Boyett JM, Hancock ML, Pratt CB, Meyer WH, Crist WM. Outcome of treatment for childhood cancer in black as compared with white children: the St. Jude Children’s Research Hospital experience, 1962 through 1992. JAMA 273:633-637, 1995.
  • Mahmoud HH, Rivera GK, Hancock ML, Krance RA, Kun LE, Behm FG, Ribeirio RC, Sandlund JT, Crist WM, Pui C-H. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med 329:314-319, 1993.
  • Pui C-H, Ribeirio RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, Head DR, Behm FG, Mahmoud MH, Sandlund JT, Crist WM. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325:1682-1687, 1991.
  • Pui C-H, Hancock ML, Raimondi SC, Head DR, Thompson E, Wilimas J, Kun LE, Bowman LC, Crist WM, Pratt CB. Myeloid neoplasia in children treated for solid tumours. Lancet 336:417-421, 1990.
  • Pui C-H, Behm FG, Raimondi SC, Dodge RK, George SL, Rivera GK, Mirro J Jr, Kalwinsky DK, Dahl GV, Murphy SB, Crist WM, Williams DL. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 321:136-142, 1989.